Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093923 · ClinicalTrials.gov registry record · Phase 1
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02093923 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 38 participants.
The verdict
NCT02093923, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
Interventions
- DRUG Placebo
- DRUG DX-2930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2015-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093923
The ClinicalTrials.gov registry entry for NCT02093923 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02093923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093923 about?
NCT02093923 is a clinical study titled "A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
What is the current status of trial NCT02093923?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-05-14. Estimated completion is 2015-05-18.
What interventions are being tested in trial NCT02093923?
The interventions under investigation include: Placebo (DRUG), DX-2930 (DRUG).
Who is sponsoring clinical trial NCT02093923?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.